Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with...

Keywords

BortezomibMonoclonal antibodyMultiple myelomaInsulin-like growth factorMonoclonalAntibodyInternal medicineMedicineCancer researchReceptorOncologyGrowth factorImmunology

Affiliated Institutions

Related Publications

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan , Shannon J. Turley , Dorothee Nickles +39 more

Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancer...

2018 Nature 5078 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Elizabeth Buck , Alexandra Eyzaguirre , Sharon Barr +7 more

Abstract Overexpression and enhanced activation of the epidermal growth factor receptor (EGFR) is frequently observed in human carcinomas. Inhibitors of EGFR signaling have show...

2007 Molecular Cancer Therapeutics 186 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Sharon Barr , Stuart Thomson , Elizabeth Buck +10 more

Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mes...

2008 Clinical & Experimental Metastasis 199 citations

Publication Info

Year: 2011
Type: letter
Volume: 25
Issue: 5
Pages: 872-874
Citations: 56
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Philippe Moreau, 
                                
                                    Federica Cavallo, 
                                
                                    Xavier Leleu
                                
                                et al.
                            
                            (2011). 
                            Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. 
                            Leukemia
                            , 25
                            (5)
                            , 872-874.
                            https://doi.org/10.1038/leu.2011.4
                        

Identifiers

DOI: 10.1038/leu.2011.4